Loading...
OTCM
JNGHF
Market cap52bUSD
Sep 28, Last price  
0.07USD
Name

Jiangsu Hengrui Pharmaceuticals Co Ltd

Chart & Performance

D1W1MN
OTCM:JNGHF chart
P/E
0.39
P/S
0.10
EPS
1.21
Div Yield, %
—
Shrs. gr., 5y
0.48%
Rev. gr., 5y
2.53%
Revenues
31.43b
+12.32%
1,422,456,9041,959,660,1212,392,561,1593,028,960,8813,744,106,2694,550,391,7685,435,067,5606,203,074,3547,452,253,0879,315,960,16711,093,724,00013,835,629,00017,417,901,00023,288,577,00027,734,599,00025,905,526,00021,275,271,00022,819,785,00027,984,605,00031,431,028,984
Net income
7.71b
+21.69%
206,647,797412,921,287422,947,064665,730,889724,173,302876,611,0611,077,384,7641,238,110,6351,515,568,8632,171,571,5452,588,952,0953,216,647,9984,065,609,7165,328,027,5196,328,383,2194,530,217,5503,906,375,0674,302,435,9306,336,527,0147,711,054,811
CFO
11.29b
+52.06%
266,175,427218,873,724117,459,736439,116,229385,945,810527,357,720958,368,8911,364,958,6661,574,306,0242,277,293,1222,592,628,3952,547,385,4162,774,212,7343,816,832,8673,431,934,8054,218,816,0531,265,264,6317,643,665,0747,422,753,03811,286,870,260

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged in the full spectrum of pharmaceutical operations, from the initial discovery and development of medications to their manufacturing and worldwide distribution. The company is actively advancing a substantial pipeline of drug candidates, which includes Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403. These prospective treatments are aimed at a diverse range of medical conditions, primarily focusing on oncology, metabolic disorders, pain management, and autoimmune diseases, among others. The enterprise was founded in 1970 and maintains its corporate headquarters in Lianyungang, China.
URL
https://www.hengrui.com/
IPO date
Oct 18, 2000
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT